Skip to main content
Equibles
INKT $9.34 -1.99%
INKT logo
INKT · MiNK Therapeutics, Inc.
Track INKT — free

Use INKT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research INKT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$9.34 -0.19 (-1.99%) At close · Nov 13 Play latest call Q2 2026 earnings call transcript
Rebalance outlook locked
Going-concern doubt — flagged Nov 12, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Because the completion of anticipated funding is not entirely within our control, we are required to disclose that substantial doubt exists about our ability to continue as a going concern for a period of one year after the date of filing of this Quarterly Report on Form 10-Q.”
View the 10-Q filed Nov 12, 2026
Market Cap
$47.95M
Shares
5.13M
Volume · Nov 13 19.03K Avg daily vol (3M) 14.64K
All webcasts

Earnings call · FY2026 Q3

MiNK Therapeutics, Inc. (INKT) Q3 2026 Earnings Call

Concluded Nov 11, 2026
Nov 11, 2026
Period
FY2026 Q3
Runtime
—
Sources
2 artifacts
Revenue $200,000
Diluted EPS -$0.50
Net income -$2.55M
Open full screen 8-K 10-Q

Executive readout · one minute

What the filings say

8-K earnings release · filed Nov 12, 2026
MiNK Therapeutics reported $0.2 million in first pre-commercial product revenue from agenT-797, while its randomized Phase 2 ARDS trial continued enrolling, with U.S. dosing expected before year-end 2026 and data expected 2H2027.
10-Q report · filed Nov 12, 2026
MiNK Therapeutics reported $7.5 million in cash as of September 30, 2026 and substantial doubt about its ability to continue as a going concern; it also recognized first pre-commercial agenT-797 revenue of approximately $0.2 million.

The audio replay and transcript follow the call.

Research coverage

2 live sources

Open each available source without leaving this research workspace.

Research materials

Open the source you need; every reader stays inside this workspace.

8-K earnings release Filed Nov 12, 2026 10-Q report Filed Nov 12, 2026 Company webcastOpen the original investor-relations page
Full-screen source Call document

INKT alerts

MiNK Therapeutics, Inc.

Create a free account or sign in to receive transcript alerts at your email address.

Continue to sign in
Read transcripts like this one from Claude, ChatGPT or your own code with the earnings call transcript API →

Embed MiNK Therapeutics, Inc. earnings calls on your site

Pick a widget, match your page, then paste the code where it should appear.

Widget
Theme
Accent color Pro

Match your site's colors with Pro. The Equibles credit stays on every plan.

Embed code 

                    
The widget credits Equibles and keeps the link below it on every plan.

                

            


            

                Preview